A phase II study of the effects of Herceptin [trastuzumab] in patients with locally advanced HER-2/NEU overexpressing breast cancer.

Trial Profile

A phase II study of the effects of Herceptin [trastuzumab] in patients with locally advanced HER-2/NEU overexpressing breast cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Docetaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Mar 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 02 May 2011 Planned end date changed from 1 Sep 2010 to 1 Sep 2012as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top